COAG · Hemab Therapeutics Holdings, Inc.
$54.94
+0.99 (+1.84%)
At close · Aug 14
Market Cap
$2.57B
Shares
46.71M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Laura Tadvalkar, Ph.D. | member of the Company's board of directors | Resigned | 2026-05-11 |
Key facts
CIK
2114044
CUSIP
423494103
13F (30d)
61 filings
57 filers
Visit website
Investor relations